The emerging role of allergic inflammation in adverse reactions after coronary stent implantation

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 70-71

  Niccoli, Giampaolo ^a   Sgueglia, Gregory A ^a,b   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SANTA MARIA GORETTI HOSPITAL   (Italy)

Author keywords

Allergy; Coronary stent; In stent restenosis; Stent thrombosis

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; PACLITAXEL; RAPAMYCIN;

ACUTE CORONARY SYNDROME; BARE METAL STENT; CORONARY STENT; DRUG ELUTING STENT; EOSINOPHIL; IN-STENT RESTENOSIS; KOUNIS SYNDROME; NOTE; PRIORITY JOURNAL; STENT THROMBOSIS;

EOSINOPHIL CATIONIC PROTEIN; FEMALE; HUMANS; MALE; STENTS;

EID: 79960276950     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.048     Document Type: Note

References (33)

1. Niccoli G., Montone R.A., Ferrante G., Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010, 56:1783-1793.
2. Toutouzas K., Colombo A., Stefanadis C. Inflammation restenosis after percutaneous coronary interventions. Eur Heart J 2004, 25:1679-1687.
3. Montone R.A., Ferrante G., Baca M., Niccoli G. Predictive value of C-reactive protein after drug-eluting stent implantation. Future Cardiol 2010, 6:167-179.
4. Park D.W., Yun S.C., Lee J.Y., et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009, 120:1987-1995.
5. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007, 370:937-948.
6. Wessely R., Kastrati A., Schomig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med 2005, 143:392-394.
7. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006, 119:1056-1061.
8. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 2004, 109:701-705.
9. Cook S., Ladich E., Nakazawa G., et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009, 120:391-399.
10. Kounis NG, Tsigkas G, Almpanis G, Kounis GN, Mazarakis A, Hahalis G. Coronary stent implantation, eosinophils and the Kounis hypersensitivity associated acute coronary syndrome. Atherosclerosis 2011 Mar 2. [Epub ahead of print].
11. Venge P., Bystrom J., Carlson M., et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999, 29:1172-1186.
12. Venge P., Bystrom J. Eosinophil cationic protein (ECP). Int J Biochem Cell Biol 1998, 30:433-437.
13. Chihara J., Yamamoto T., Kurachi D., Kakazu T., Higashimoto I., Nakajima S. Possible release of eosinophil granule proteins in response to signaling from intercellular adhesion molecule-1 and its ligands. Int Arch Allergy Immunol 1995, 108(Suppl. 1):52-54.
14. Hernnas J., Sarnstrand B., Lindroth P., Peterson C.G., Venge P., Malmstrom A. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur J Cell Biol 1992, 59:352-363.
15. Niccoli G., Schiavino D., Belloni F., et al. Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents. Eur Heart J 2009, 30:1340-1347.
16. Niccoli G., Sgueglia G.A., Conte M., et al. Eosinophil cationic protein and clinical outcome after bare metal stent implantation. Atherosclerosis 2011, 215:166-169. Epub 2010 Dec 8.
17. Budinger L., Hertl M. Immunologic mechanisms in hypersensitivity reactions to metal ions: an overview. Allergy 2000, 55:108-115.
18. Koster R., Vieluf D., Kiehn M., et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 2000, 356:1895-1897.
19. Yutani C., Ishibashi-Ueda H., Suzuki T., Kojima A. Histologic evidence of foreign body granulation tissue and de novo lesions in patients with coronary stent restenosis. Cardiology 1999, 92:171-177.
20. Kawano H., Koide Y., Baba T., et al. Granulation tissue with eosinophil infiltration in the restenotic lesion after coronary stent implantation. Circ J 2004, 68:722-723.
21. Rittersma S.Z., Meuwissen M., van der Loos C.M., et al. Eosinophilic infiltration in restenotic tissue following coronary stent implantation. Atherosclerosis 2006, 184:157-162.
22. Nakatani M., Takeyama Y., Shibata M., et al. Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol 2003, 12:40-48.
23. Finn A.V., Nakazawa G., Joner M., et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007, 27:1500-1510.
24. Ribichini F., Joner M., Ferrero V., et al. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol 2007, 50:176-185.
25. Rittersma S.Z., van der Wal A.C., de Winter R.J. Eosinophilic tissue response several weeks after sirolimus-eluting Cypher stent implantation within a bare metal stent in a coronary saphenous vein graft. Catheter Cardiovasc Interv 2006, 67:38-40.
26. van der Giessen W.J., Lincoff A.M., Schwartz R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996, 94:1690-1697.
27. Wang J.G., Mahmud S.A., Thompson J.A., Geng J.G., Key N.S., Slungaard A. The principal eosinophil peroxidase product HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006, 107:558-565.
28. Rohrbach M.S., Wheatley C.L., Slifman N.R., Gleich G.J. Activation of platelets by eosinophil granule proteins. J Exp Med 1990, 172:1271-1274.
29. Hamid Q., Tulic M. Immunobiology of asthma. Annu Rev Physiol 2009, 71:489-507.
30. Kornowski R., Hong M.K., Tio F.O., Bramwell O., Wu H., Leon M.B. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998, 31:224-230.
31. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
32. Nebeker J.R., Virmani R., Bennett C.L., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006, 47:175-181.
33. Kounis N.G., Kounis G.N., Kouni S.N., Soufras G.D., Niarchos C., Mazarakis A. Allergic reactions following implantation of drug-eluting stents: a manifestation of Kounis syndrome?. Am Coll Cardiol 2006, 48:592-593.